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Abstract: BACKGROUND A clinical research application must be submitted for approval by a compe-
tent ethics committee (EC) before a study can be executed. There is very limited information on how
such submissions could be optimised, especially regarding research in children and adolescents, which
requires particular caution and age-adapted patient information. METHODS We assessed all research
applications from the University Children’s Hospital Zurich submitted to the EC of the Canton of Zurich
in 2014–2015, i.e., in the first two years after Switzerland’s new Human Research Act came into effect.
Moreover, we validated our findings by assessing a randomly selected sample of applications from the same
hospital in 2018–2019. RESULTS We assessed a total of 86 applications from 2014–2015, originating from
29 departments and sub-specialties. The EC judged that it was not responsible for three applications
and declined an assessment for another three because the studies had already been conducted. Thus, we
included 80 applications in the present analysis (18 clinical trials, 52 research projects, 10 further use
projects). Applicants withdrew four applications before the EC’s final decision and the EC rejected two
after assessment. The EC had objections in 46 (62%) of the remaining 74 applications. Formal, including
formal legal, objections (n = 503) and legal objections (n = 287) accounted for the vast majority of objec-
tions. There were also 71 ethical and 82 scientific objections. The most frequent formal and formal legal
objections were incomplete or missing age-adapted patient information (49%) and incorrect templates
for informed consent and signature forms (46%). A review of the 20 randomly selected applications from
2018–2019 confirmed that four out of the five most frequent deficiencies relating to informed consent
were identical to those observed in the 2014–2015 applications. CONCLUSIONS Careful preparation of
submission documents by the investigators and close adherence to formal and legal requirements have the
potential to considerably optimise and expedite the EC review process, and thus the commencement of
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Summary
BACKGROUND: A clinical research application must be
submitted for approval by a competent ethics committee
(EC) before a study can be executed. There is very limited
information on how such submissions could be optimised,
especially regarding research in children and adolescents,
which requires particular caution and age-adapted patient
information.
METHODS: We assessed all research applications from
the University Children’s Hospital Zurich submitted to the
EC of the Canton of Zurich in 2014–2015, i.e., in the
first two years after Switzerland’s new Human Research
Act came into effect. Moreover, we validated our findings
by assessing a randomly selected sample of applications
from the same hospital in 2018–2019.
RESULTS: We assessed a total of 86 applications from
2014–2015, originating from 29 departments and sub-spe-
cialties. The EC judged that it was not responsible for
three applications and declined an assessment for another
three because the studies had already been conducted.
Thus, we included 80 applications in the present analysis
(18 clinical trials, 52 research projects, 10 further use pro-
jects). Applicants withdrew four applications before the
EC’s final decision and the EC rejected two after assess-
ment. The EC had objections in 46 (62%) of the remaining
74 applications. Formal, including formal legal, objections
(n = 503) and legal objections (n = 287) accounted for
the vast majority of objections. There were also 71 ethical
and 82 scientific objections. The most frequent formal and
formal legal objections were incomplete or missing age-
adapted patient information (49%) and incorrect templates
for informed consent and signature forms (46%). A review
of the 20 randomly selected applications from 2018–2019
confirmed that four out of the five most frequent deficien-
cies relating to informed consent were identical to those
observed in the 2014–2015 applications.
CONCLUSIONS: Careful preparation of submission docu-
ments by the investigators and close adherence to formal
and legal requirements have the potential to considerably
optimise and expedite the EC review process, and thus
the commencement of the clinical research.
Keywords: age-adapted patient information, formal defi-
ciencies, legal deficiencies, ethical deficiencies, scientific
deficiencies
Introduction
Ethical approval of a clinical research study is essential be-
fore it can start [1], and the legal requirements for such ap-
proval may differ between countries [2]. In Switzerland,
research in humans is regulated at the national level by
the Human Research Act (HRA) and three associated or-
dinances, which came into effect on 1 January 2014 [3].
Legal requirements for clinical studies with pharmaceuti-
cals and medical devices were for the most part transferred
from the Therapeutic Products Act (TPA) to the HRA and
its ordinances. The new law generated changes for inves-
tigators and ethics committees (ECs). The Swiss HRA dif-
ferentiates between clinical trials, which evaluate an in-
tervention and are regulated by the Ordinance on Clinical
Trials (ClinO) [4], and research projects, i.e., the collection
of health-related personal data and the sampling of biolog-
ical material, which are regulated by the Ordinance on Hu-
man Research, also called the Human Research Ordinance
(HRO) [5]. The HRO also regulates the further use of ex-
isting data and biological material for research purposes.
Hence, the HRA regulates various kinds of research in hu-
mans. Since the HRA uses a risk-based approach, clinical
research is segregated into risk categories, with gradated
requirements for authorisation, monitoring and reporting.
The preparation of applications for EC approval is thus de-
manding due to the legal requirements, and enthusiastic in-
vestigators tend to underestimate the administrative and le-
gal duties associated with research in humans. Therefore,
a cumbersome submission of a planned clinical study for
EC approval may delay or, in the worst case, in prevent
the commencement of the research. Writing applications
for clinical research in paediatrics is even more demand-
ing, since the vulnerability of children and their age-adapt-
ed information must be considered [6].
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The primary aim of this study was to identify the most
common objections to paediatric applications made by the
EC of the Canton of Zurich in the first two years after the
new HRA came into effect. Our results will provide guid-
ance to investigators on optimising future paediatric re-
search applications.
Materials and methods
We reviewed all research applications submitted from the
University Children’s Hospital Zurich to the EC of the
Canton of Zurich in 2014–2015. We extracted relevant data
from the EC’s electronic database Evidence® on the basis
of pre-defined categories. These included the medical dis-
cipline of origin, the nature of the research and the poten-
tial objections by the EC, segregated into formal (including
formal legal), legal, ethical and scientific items (total 41).
Two authors (HÖ; EB) reviewed the ECs’ responses in a
first step, and all the authors discussed and verified the re-
sponses in a second step.
In order to evaluate the validity of our findings, we as-
sessed a sample of 20 randomly selected paediatric re-
search applications from 2018–2019. We extracted the data
from the electronic submission platform Business Admin-
istration System for Ethics Committees (BASEC), which
has been used by all ECs in Switzerland as an information
and management system since 2016. Initially, one author
(PK) reviewed the applications from 2018–2019 using the
above procedure. Then two other authors (EB and DN)
verified the EC’s responses.
Cooperation between the University Children’s Hospital
Zurich and the EC of the Canton Zurich was agreed in
writing. Data extraction took place in the offices of the
EC. Confidential handling of the data was assured through-
out. The management of the University Children’s Hospi-
tal consented in writing to the reviewing of all applications.
The present study required no ethics committee approval.
Results
A total of 86 research applications from 29 departments
and sub-specialties from the University Children’s Hos-
pital, Zurich were submitted during the 2-year period
2014–2015. The EC declined an assessment for three of
these applications, as the studies had already been conduct-
ed, and judged that it was not responsible for three oth-
er applications. Thus, we included 80 applications in this
analysis: 18 clinical trials, 52 research projects and 10 fur-
ther use projects. The majority of applications were mono-
centric (n = 58; 72.5%); the EC Zurich was the leading
committee in 12 of the 22 multicentre trials (10 clinical tri-
als, 10 research projects and 2 further use projects).
Applicants withdrew four applications before the EC’s fi-
nal decision and the EC rejected two after assessment. The
EC had objections in 46 (62%) of the remaining 74 appli-
cations. The EC requested a second assessment for seven
(9.2%) applications, three of which were eventually reject-
ed, and a third assessment for one application.
Table 1 lists the most frequent formal (including formal le-
gal), legal, ethical and scientific/medical objections made
by the EC to the 74 applications used for analysis. “For-
mal” objections addressed deficiencies in the form of the
application and included the lack of a signature, omissions
in the list of co-workers, linguistic weaknesses and missing
documents. “Formal legal” objections addressed deficien-
cies related to the letter of the law and included, e.g., faults
in the process of encryption and anonymisation of data.
“Scientific/medical” objections included aspects surround-
ing the research question, such as the inclusion and exclu-
sion criteria or the description of the study population. The
vast majority of objections were formal and legal ones.
Table 2 presents the frequencies with which modifications
regarding parent/patient information or informed consent
were requested by the EC in all 74 applications. Objections
regarding parent/patient information were the most fre-
quent, followed by objections regarding the consent form.
Almost half the applications provided incomplete or no
age-adapted patient information, and in 45% of applica-
tions, information about the anonymisation of the data gen-
erated and the destruction of biological material once the
study was completed, including for those who withdrew
from the study prematurely, was either not given or was in-
correct.
Table 1: Objections regarding formal and formal legal deficiencies and ethical, legal or scientific requirements in the 74 submissions analysed.
Objections (total n) Description of the most frequent objections
Formal and formal legal defi-
ciencies
(n = 503)
Confusion of encryption and anonymisation
Addressing minors or parents incorrectly on the information sheet
Unclear specification of different age groups
Wrong use of terms when custodian, guardian or legal representative is meant
Use of overly technical language not understandable by laypersons in the information sheet
Non-fulfilment of ethical re-
quirements
(n = 71)
Freedom of choice as to whether or not a research subject wants to be informed about incidental findings missing
Inadequate reflection period between informing about a research project and seeking written consent
Insufficient information about study procedures and what is expected of the research subjects
Benefit-risk relationship too positive or potential risks underestimated in the informed consent form
Preselection of research subjects by a person not authorised to access medical record without having obtained informed consent
Non-fulfilment of legal require-
ments
(n = 287)
Insufficient description in the protocol of data encryption or anonymisation processes, storage of the code and data access rights
No consideration of adolescents’ right to legally consent in research with only minimal risks
Non-separation of consent to a specific research project and consent to the further use of data/samples in future research projects
Documentation of identifying information in the case record forms, e.g. full date of birth
Deficient or unclear instructions with respect to contraception
Non-fulfilment of general scien-
tific requirements
(n = 82)
No specification of inclusion/exclusion criteria
Lack of medically relevant exclusion criteria
Lack of declaration of the radiation dose in projects with radiological examinations
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Apart from shortcomings concerning informed consent,
the two most frequent ethical objections were information
about study intervention and handling of/information
about unexpected findings. The most frequent legal objec-
tions requiring revision concerned data protection, data re-
tention and procedure in the case of consent revocation.
Objections concerning further use of data beyond the
study, instructions about contraception in applications for
clinical trials, involvement of children/adolescents capable
of judgement and anonymisation in research projects were
less frequent. The most frequent medical or scientific ob-
jections were related to the risks or description of the pro-
posed intervention, the description of the study population,
and follow-up intervention. In applications for research
projects, the most frequent medical or scientific objections
were inclusion/exclusion criteria, description of study pop-
ulation, risks of the intervention and description of the in-
tervention.
The 20 paediatric applications from 2018–2019 that were
selected randomly to validate the data from 2014–2015
showed a proportional distribution of application types
(eight further use projects; seven projects involving per-
sons; five clinical studies) comparable to those from
2014–2015. The analysis of the 2018–2019 applications
revealed that the most common deficiencies concerned the
data encryption or anonymisation process, the storage of
the code and the data access rights, as observed in the
analysis of the 2014–2015 applications. Furthermore, four
out of the five most frequent deficiencies with respect to
informed consent had already been observed in the analy-
sis of the 2014–2015 applications (table 3 and data not
shown).
Discussion
Our analysis reveals that the EC eventually approved the
vast majority of applications, but that more than one in two
submissions were returned to the applicants for modifica-
tion with multiple objections, mostly of a formal, formal
legal or legal nature. Thus, careful preparation of the sub-
mission documents by the investigators has the potential
to considerably expedite final approval by the EC and the
commencement of the clinical research.
An important observation here is that the overwhelming
majority of the objections raised by the EC were of a for-
mal or formal legal nature and due to the legal require-
ments not being fulfilled. This implies that many of the
EC’s objections could be prevented by the investigators
considering the formal issues and legal requirements more
carefully. Considering legal requirements such as data pro-
tection, retention or further use, for which clear acts or
rules exist, requires less effort than considering issues such
Table 2: Frequencies of modifications requested by the ethics committee regarding parent/patient information or the consent form from a total of 74 submissions.
n (%)
Parent/patient information (PI)
Age-adapted patient information incomplete or missing 36 (49)
Information about anonymisation of data generated and destruction of biological material once the study was completed, including for those who
withdraw from the study prematurely, not given or wrong
33 (45)
Insufficient/misleading (scientific, organisational) information 24 (32)
Inapt information on who decides about communication of unexpected results 9 (12)
No information about right of patients/parents to withdraw from study at any time 8 (11)
No information about right of patients/parents to be informed at any time 6 (8)
Missing information about costs 5 (7)
Superfluous information 4 (5)
Phone number/e-mail address of medical contact person not provided 3 (4)
Stationery on form incorrect 3 (4)
Informed consent (IC) – signature form
Template form for parents/paediatric patients not correctly adapted or wrong example form used 33 (45)
Version of patient/parent information used not stated or incorrect 13 (18)
Paragraph regarding information about unexpected results incorrect 7 (9)
Missing example of general consent 3 (4)
Stationary on form incorrect 3 (4)
Missing statement about version of signature form 2 (3)
Table 3: Most frequent overall deficiencies or deficiencies with respect to informed consent in 20 randomly selected submissions from 2018–2019 in descending order.
Deficiencies Specification
Overall Deficiencies in the data encryption or anonymisation process, storage of the code and data access rights
Protocol not signed by all parties or study sites
Unclear status of informed consent to further use of data or samples for research purposes
Statement that legal requirements in CH are respected missing or incomplete (primarily international projects)
Deficiencies with respect to handling of data/samples after withdrawal of consent
With respect to informed consent Use of overly technical language not well understood by laypersons in the information sheet
Benefit-risk relationship too positive or potential risks underestimated in the informed consent form
Freedom of choice as to whether a research subject wants to be informed about incidental findings or not missing
Deficiencies in the information sheet with respect to data protection rights
Non-separation of consent to a specific research project and consent to the further use of data/samples in future
research projects
Bold text = deficiencies that were also frequently observed in 2014 and 2015
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as patient information and informed consent, which may
need meticulous phrasing and editing. These latter are es-
pecially challenging in paediatric studies as they require
additional, age-adapted patient information or informed
consent. Nevertheless, addressing patients and volunteers
with linguistic correctness independently of their age, as
well as communicating clearly with them, are important
prerequisites for successful recruitment to and enhanced
compliance during a study. A subsequent analysis of ran-
domly selected applications from four years later revealed
that formal (including formal legal) or legal deficiencies
similar or identical to those observed in 2014–2015 were
still among the most frequent objections. Importantly, the
application samples from 2014–2015 and 2018–2019 are
broadly comparable. Therefore, time invested in preparing
study documents for ECs will pay dividends by allowing a
clinical study to be executed more quickly.
A motivating factor for investigators is our observation
that the EC rejected only a very small proportion of sub-
missions. Few investigations have so far addressed the per-
formance of ECs, and research is needed to understand
how ECs accomplish their objectives, what issues they
consider important, the quality of the EC review process,
and how effective ECs are at protecting human research
participants [7–11]. Nevertheless, here the EC very rarely
opposed the execution of a study. In contrast, the EC re-
view process most often resulted in objections regarding
formal and formal legal issues only, of which age-adapted
patient information and issues related to informed consent
were by far the most frequent. Linguistic improvements
to informed consent, however, have been a matter of de-
bate, as they may reduce patient enrolment but not increase
patients’ understanding [12]. It is of note that the EC did
not here raise fundamental ethical questions relating to
the context of paediatric research, particularly participants’
safety. The criticisms voiced do not mirror poor design or
ill formulation by the investigators, but rather alert them to
inconsistencies. Investigators are in most cases more profi-
cient in their specific research topics than EC members.
Our study has limitations as a retrospective study at just
one University Children’s Hospital and the single corre-
sponding competent EC. The latter might be a more impor-
tant limitation, as ECs may differ in their judgment. This
may impact on the formal and medical/scientific issues,
but is unlikely to affect the legal issues and is even less
likely to affect the ethical issues. Thus, our results can be
generalised with respect to legal and ethical issues.
Improved, more careful preparation of submission docu-
ments, thereby respecting well-defined legal issues, and
editing texts with the support of Clinical Trial Units may
substantially help investigators to optimise and expedite
their clinical research and thus benefit patients. Notably,
swissethics, the umbrella organisation of all seven research
ethics committees in Switzerland, has generated templates
for all types of clinical research (www.swissethics.ch/tem-
plates.html). This reflects an acknowledgment of the most
frequent objections issued by the ECs and aims to support
clinical investigators. From a more general point of view,
the help of patients’ and parents’ organisations should be
sought whilst engineering a research project and phrasing
the patient information.
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